Prosecution Insights
Last updated: November 04, 2026
Application No. 18/900,015

COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES

Non-Final OA §102§103§DOUBLEPATENT
Filed
Sep 27, 2024
Priority
Aug 21, 2017 — provisional 62/548,301 +4 more
Examiner
ANDERSON, REBECCA L
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Acadia Pharmaceuticals Inc.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
2m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
772 granted / 1052 resolved
+13.4% vs TC avg
Strong +24% interview lift
Without
With
+23.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
49 currently pending
Career history
1109
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
18.7%
-21.3% vs TC avg
§102
24.2%
-15.8% vs TC avg
§112
33.0%
-7.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1052 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Claims 1, 3-5, 10-11, 13-14, 23-24, 27, 29, 33, 35, 39, 41, and 49-63 are currently pending in the instant application and are rejected. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3-5, 10, 11, 13, 14, 23, 24, 27, 29, 33, 35, 39, 41, and 49-63 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-38 of U.S. Patent No. 11,345,693. Although the claims at issue are not identical, they are not patentably distinct from each other because the conflicting claims claim a genus within the instant claims, conflicting claim 1, with conflicting claim 21 claiming: PNG media_image1.png 390 348 media_image1.png Greyscale PNG media_image2.png 168 344 media_image2.png Greyscale which are the 15 species of instant claims 49-53. Additionally, conflicting claims 24-38 claim the same species as found in instant claims 49-63, the only difference is conflicting claims 24-38 include hydrates, solvates, or deuterated analogues thereof, whereas the instant claims 49-63 claim the compound or a pharmaceutically acceptable salt thereof. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 3, 4, and 11 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO2010/111353 (IDS filed 1/28/2025). WO2011/111353 discloses the compound: PNG media_image3.png 126 238 media_image3.png Greyscale which corresponds to the instant formula (I): PNG media_image4.png 172 510 media_image4.png Greyscale , for example, at least wherein R1 is F; R1a, R1b, R1c, and R1d are hydrogen; m is 1; R4a and R4b are each hydrogen; X is O; n is 1; R5a and R5b are hydrogen; R2 is C1 alkoxy; three of R2a, R2b, R2c, and R2d are hydrogen with one of R2b or R2c being hydroxyl; R8 is hydrogen; q and p are each 0; and R3 is hydrogen. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 3, 4, 5, and 11 is/are rejected under 35 U.S.C. 103 as being unpatentable over US Pre-Grant Publication 2003/0069276. US Pre-Grant Publication 2003/0069276 discloses the compound of the formula I, page 1: PNG media_image5.png 156 256 media_image5.png Greyscale wherein R2 and R3 independently of each other can be hydrogen, aryl, or substituted aryl. Paragraphs [0110], [0112], and [0116] on page 11 provide preferences to R2 and R3 being most preferably hydrogen and substituted phenyl [0114], PNG media_image6.png 114 390 media_image6.png Greyscale Page 49 provides the compound PNG media_image7.png 366 820 media_image7.png Greyscale in table I, page 49. The compound corresponds to applicant’s formula (I): PNG media_image4.png 172 510 media_image4.png Greyscale , for example, at least wherein R1 is methyl; R1a, R1b, and R1c are hydrogen; R1d is methyl; m is 1; R4a and R4b are each hydrogen; X is O; n is 0; R2, R2a, R2b, R2c, and R2d are each hydrogen; R8 is hydrogen; q and p are each 0; and R3 is substituted alkyl. The difference between the compound on page 49 and the claimed invention is the compound of the prior art has the position equivalent to Applicant’s instant R2 as hydrogen, whereas the instant claims require R2 to not be hydrogen, hydroxy or benzyloxy. The difference is therefore one of hydrogen versus methyl. However, the prior art provides preference towards R2 and R3 to be hydrogen and substituted phenyl, wherein most preferably substituted phenyl can be substituted with alkyl, see paragraphs [0114] and [0116]. Additionally, it is well established that the substitution of methyl for hydrogen on a known compound is not a patentable modification absent unexpected or unobvious results. In re Wood, 199 U.S.P.Q. 137 (C.C.P.A. 1978) and In re Lohr, 137 U.S.P.Q. 548, 549 (C.C.P.A. 1963). The motivation to make the claimed compounds derives from the expectation that structurally similar compounds would possess similar activity as found in the prior art which is found on page 53 as pharmaceutical compositions useful as chemotherapeutic agents, inhibitors of viral replication and modulators of the immune system, for example. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 23 October 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

Sep 27, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773411
COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND PLATINUM-BASED ANTICANCER AGENT
6y 3m to grant Granted Oct 27, 2026
Patent 12759994
ISOLATION METHOD FOR LACTIDE RACEMATE
3y 0m to grant Granted Oct 13, 2026
Patent 12759992
COMPOSITIONS AND METHODS FOR INHIBITING IDO1
2y 10m to grant Granted Oct 13, 2026
Patent 12735385
ALKYLSULFENYL THIOCARBONATES: PRECURSORS TO HYDROPERSULFIDES POTENTLY ATTENUATE OXIDATIVE STRESS
2y 10m to grant Granted Sep 15, 2026
Patent 12729196
N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
3y 2m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+23.6%)
2y 4m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1052 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month